Brokerages Anticipate Teladoc Health, Inc. (NYSE:TDOC) Will Post Earnings of -$0.59 Per Share

Brokerages forecast that Teladoc Health, Inc. (NYSE:TDOC) will announce earnings per share of ($0.59) for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Teladoc Health’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.92). Teladoc Health reported earnings per share of ($0.40) in the same quarter last year, which would indicate a negative year-over-year growth rate of 47.5%. The company is scheduled to report its next earnings report on Wednesday, May 5th.

On average, analysts expect that Teladoc Health will report full-year earnings of ($2.06) per share for the current fiscal year, with EPS estimates ranging from ($3.32) to ($0.29). For the next fiscal year, analysts forecast that the company will report earnings of ($0.90) per share, with EPS estimates ranging from ($3.10) to $1.15. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Teladoc Health.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 24th. The health services provider reported ($3.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($2.82). Teladoc Health had a negative return on equity of 6.15% and a negative net margin of 12.71%.

Several equities research analysts have weighed in on the company. Evercore ISI began coverage on Teladoc Health in a research report on Tuesday, December 22nd. They issued an “in-line” rating and a $215.00 target price on the stock. Jefferies Financial Group cut their price target on Teladoc Health from $264.00 to $248.00 and set a “hold” rating on the stock in a report on Wednesday, March 3rd. Oppenheimer increased their price objective on Teladoc Health from $250.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, March 3rd. BTIG Research lifted their price objective on shares of Teladoc Health from $260.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, January 26th. Finally, Credit Suisse Group boosted their price target on shares of Teladoc Health from $296.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, March 4th. Fourteen analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $241.38.

In other news, insider Arnnon Geshuri sold 1,750 shares of Teladoc Health stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $298.26, for a total transaction of $521,955.00. Following the completion of the transaction, the insider now directly owns 102,569 shares in the company, valued at $30,592,229.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Adam C. Vandervoort sold 2,610 shares of the firm’s stock in a transaction that occurred on Wednesday, February 3rd. The shares were sold at an average price of $269.85, for a total value of $704,308.50. Insiders have sold 674,374 shares of company stock worth $135,744,738 in the last ninety days. Insiders own 3.42% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. General Catalyst Group Management LLC purchased a new position in shares of Teladoc Health in the 4th quarter worth approximately $1,610,161,000. Aequim Alternative Investments LP increased its stake in shares of Teladoc Health by 33,044.2% during the 4th quarter. Aequim Alternative Investments LP now owns 3,447,000 shares of the health services provider’s stock worth $1,071,000 after purchasing an additional 3,436,600 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Teladoc Health by 148.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,221,549 shares of the health services provider’s stock worth $644,181,000 after purchasing an additional 1,927,001 shares during the period. Nikko Asset Management Americas Inc. grew its holdings in Teladoc Health by 173.4% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 2,824,067 shares of the health services provider’s stock valued at $564,700,000 after buying an additional 1,791,008 shares in the last quarter. Finally, Baillie Gifford & Co. raised its holdings in shares of Teladoc Health by 16.0% in the 4th quarter. Baillie Gifford & Co. now owns 7,238,667 shares of the health services provider’s stock valued at $1,447,444,000 after acquiring an additional 996,628 shares in the last quarter. 51.77% of the stock is owned by institutional investors and hedge funds.

Teladoc Health stock traded up $0.74 during midday trading on Monday, hitting $182.00. The stock had a trading volume of 68,829 shares, compared to its average volume of 3,574,662. The stock has a market cap of $27.79 billion, a P/E ratio of -126.76 and a beta of 0.30. The business has a fifty day moving average price of $203.79 and a 200 day moving average price of $216.41. The company has a current ratio of 6.52, a quick ratio of 6.47 and a debt-to-equity ratio of 0.43. Teladoc Health has a 12 month low of $147.71 and a 12 month high of $308.00.

About Teladoc Health

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

Read More: What are catch-up contributions?

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.